|
Current issue
Archive
Online First
About the journal
Editorial board
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Special Issues
Instructions for authors
Publication charge
Editorial System
Submit your Manuscript
Open access 
|
2/2011
vol. 10 abstract:
Original paper
Podoplanin expression in malignant ovarian cancer
Barbara Marzec-Kotarska
,
Józef Kotarski
,
Marek Cybulski
,
Halina Antosz
,
Janusz Kocki
,
Wiesława Bednarek
Przegląd Menopauzalny 2011; 2: 102–105
Online publish date: 2011/04/28
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Introduction: Ovarian cancer is mostly diagnosed in postmenopausal women. The hormonal microenviron-
ment of ovarian tumour development in pre- and postmenopausal women is different. The environment may influence the molecular basis of ovarian cancer. Podoplanin is a proven marker of lymphangiogenesis and is engaged in tumour progression and metastasis. Objectives: The aim of our study was to assess podoplanin expression at the mRNA level in ovarian serous and mucinous adenocarcinoma. Material and methods : mRNA expression of podoplanin was assessed in 42 ovarian cancer patients by means of real-time PCR. Results : Podoplanin was expressed at the mRNA level in all ovarian cancer patients. It was significantly lower (p < 0.001) in cancer tissues (RQ = 4.46) than in healthy control (RQ = 13.03). No significant differences were found in podoplanin expression either between pre- and postmenopausal women or in relation to FIGO and grading Conclusion : Decreased podoplanin expression is characteristic for serous and mucinous ovarian adenocarcinoma. keywords:
podoplanin, ovarian cancer |
 |
